Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

Discover how precision biotherapeutics can transform healthcare in India by personalizing treatments based on genetic and ...

December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment for ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment opportunity for sickle cell disease and β-thalassemia. The discovery, ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $67.74, demonstrating a -6.98% change from the preceding day's closing price. This change lagged the S&P 500's 0.01% gain on the day.